Next Article in Journal
Prediction of Targets and Mechanisms of Top Ten Core “Food–Medicine Homologous Traditional Chinese Medicines” in Delaying Vascular Aging: An Integrative Computational Study
Previous Article in Journal
Inhalable Dry Powders from Lyophilized Sildenafil-Loaded Liposomes with Resveratrol or Cholesterol as a Bilayer Component
Previous Article in Special Issue
Exploring the Impact of 3-O-Methylquercetin on Wnt/β-Catenin Pathway Activity and Its Potential in Neural Processes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 19
Issue 1
10.3390/ph19010130
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates

by
Alef D. S. Lima
1,2 and
Lídia M. Lima
1,2,*
1
Laboratory for the Evaluation and Synthesis of Bioactive Substances (LASSBio®), National Institute of Science and Technology for Drugs and Medicines (INCT-INOFAR), Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
2
Graduate Program in Chemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, RJ, Brazil
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2026, 19(1), 130; https://doi.org/10.3390/ph19010130
Submission received: 30 November 2025 / Revised: 29 December 2025 / Accepted: 7 January 2026 / Published: 12 January 2026
(This article belongs to the Special Issue A Commemorative Special Issue in Honor of Professor Eliezer J. Barreiro: Early Drug Discovery: From Target Identification and Validation to Lead Optimization)
Browse Figures
Review Reports Versions Notes

Abstract

Phosphatidylinositol-3-kinases (PI3Ks) constitute an important validated therapeutic class involved in crucial cellular processes, and their dysregulation is associated with cancer initiation and progression. Nonetheless, intrinsic and acquired resistance mechanisms associated with PI3K pathway modulation have underscored the need for alternative therapeutic strategies. In this context, recent studies have shown that simultaneous inhibition of PI3K and histone deacetylases (HDAC) promotes synergistic antitumor effects in different cancer cell lines. HDACs are validated epigenetic targets that are extensively explored in clinical practice and have a pharmacophore with versatility for structural modifications, which facilitates the design of multitarget inhibitors. This review examines the rational design and synthetic evolution of dual PI3K/HDAC inhibitors, an area catalyzed by the development of fimepinostat, the first clinically evaluated agent exhibiting potent and balanced inhibition of both targets. We provide a critical overview of PI3K/HDAC multitarget inhibitors reported in recent years that have progressed to preclinical or clinical investigation, discussing the structural frameworks employed, medicinal chemistry strategies adopted, and structure–activity relationships established. Particular attention is given to advantageous molecular features as well as challenges related to toxicity, pharmacokinetic behavior, and pharmacodynamic modulation. From this comprehensive analysis, we outline key considerations and emerging design principles that may inform the next generation of PI3K/HDAC multitarget drug candidates. Insights derived from the diversity of chemical scaffolds, activity profiles, and selectivity patterns described herein may support the development of innovative therapeutic agents capable of overcoming current limitations in anticancer treatment.

Graphical Abstract

1. Introduction

Throughout the history of drug discovery, the field has been largely shaped by the classical “one molecule–one target–one disease” paradigm, which emphasizes the design of highly selective ligands to modulate individual biological targets implicated in pathological conditions [1]. However, technological advances across the biological, chemical, and health sciences have increasingly revealed the multifactorial and interconnected nature of chronic non-communicable diseases, thereby opening the way for the intentional design of multitarget therapeutic agents [2,3]. This conceptual shift has been particularly impactful in oncology, where tumor initiation and progression frequently involve the simultaneous dysregulation of multiple receptors and signaling pathways [4].
Pharmacological cancer therapy rarely relies on monotherapy. Instead, treatment commonly employs combinations of single-agent drugs—often referred to as drug combination therapy or antitumor “cocktails”—in which multiple agents are administered concomitantly, each acting through distinct yet complementary mechanisms of action [5]. Combination regimens may take the form of co-administered agents, fixed-dose combinations (single formulations containing multiple active pharmaceutical ingredients), or multitarget-directed ligands (MTDLs). The latter correspond to a single molecular entity capable of modulating more than one biological target simultaneously. Introduced by Morphy and Rankovic in 2005, the MTDL concept has since emerged as a compelling alternative to Paul Ehrlich’s early-20th-century “magic bullet” paradigm [6].
The MTDL strategy involves the use of a single active compound able to interact with two or more targets either vertically—modulating proteins within the same signaling pathway—or horizontally—acting on targets distributed across distinct biological pathways. Such simultaneous modulation can produce synergistic therapeutic effects, thereby offering a powerful approach to address complex diseases like cancer [7]. Unlike traditional combination therapies, MTDLs circumvent several limitations, including poor patient adherence, disparities in pharmacokinetic or pharmacodynamic profiles between co-administered drugs, and the risk of drug–drug interactions. Moreover, multitarget ligands may reduce required therapeutic doses, minimize systemic toxicity, and mitigate the emergence of resistance mechanisms [8].
Despite the inherent challenges—such as achieving appropriate potency and selectivity across multiple targets within a single scaffold while ensuring adequate bioavailability—numerous MTDLs have achieved regulatory approval or entered clinical development, demonstrating promising therapeutic potential in oncology. Representative examples are depicted in Figure 1 [1,9].
Among the molecular targets currently prioritized in the design of multitarget-directed ligands (MTDLs) for oncological applications, phosphoinositide 3-kinases (PI3Ks) and histone deacetylases (HDACs) have emerged as particularly relevant due to their pivotal roles in cellular homeostasis, epigenetic regulation, and tumor progression. In this review, we provide a comprehensive examination of the key signaling pathways governed by these enzyme families, outline the principal structural classes and pharmacological profiles of their inhibitors, and present a detailed medicinal chemistry analysis of dual PI3K/HDAC modulators described to date. Emphasis is placed on molecular design strategies, scaffold-hopping approaches, structure–activity relationships, and the physicochemical and pharmacokinetic considerations that have shaped the development of this multitarget chemotype.

1.1. Phosphatidylinositol-3-Kinases (PI3K)

The phosphoinositide 3-kinase (PI3K) signaling pathway constitutes a central intracellular cascade with profound influence on key cellular processes, including growth, motility, proliferation, survival, metabolic regulation, and angiogenesis [10,11]. PI3Ks comprise a family of lipid kinases located predominantly at the plasma membrane, where they catalyze the phosphorylation of the 3′-hydroxyl group of the inositol ring in phosphoinositides using adenosine triphosphate (ATP) as the phosphate donor [12]. Based on structural organization, substrate preference, and regulatory mechanisms, PI3Ks are classified into three major classes—classes I, II, and III. Class I PI3Ks, the most extensively characterized, are subdivided into class IA (isoforms α, β, and δ) and class IB (γ). Notably, class IA isoforms are predominantly implicated in the initiation and maintenance of diverse human malignancies [10,13].
Dysregulation of the PI3K pathway plays a pivotal role in tumorigenesis and cancer progression. Oncogenic activation frequently arises from aberrant PI3K expression, loss or inactivation of the lipid phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10), mutations in catalytic subunits (most commonly PIK3CA), or alterations in PI3K-associated oncogenes [14]. As a consequence, the PI3K pathway has emerged as a high-value therapeutic target in oncology, driving the intensive development of small-molecule inhibitors over recent decades.
To date, six PI3K inhibitors have received FDA approval for clinical use: Idelalisib (5), Copanlisib (6), Duvelisib (7), Alpelisib (8), Umbralisib (9), and Inavolisib (10) (Figure 2) [15,16,17,18,19,20]. With the exception of Alpelisib (8) and the more recently approved Inavolisib (10)—both indicated for the treatment of solid tumors, particularly hormone receptor–positive breast cancer—approved PI3K inhibitors have been primarily directed toward hematologic malignancies. The therapeutic relevance of these agents underscores both the importance and the complexity of selectively modulating this pathway in cancer therapy.
It is important to highlight that several clinical indications for approved PI3K inhibitors were subsequently withdrawn, particularly those granted through the FDA’s accelerated approval pathway, due to the emergence of serious safety concerns or insufficient evidence of clinical benefit in post-marketing confirmatory trials [21]. In 2022, the indications of Idelalisib (5) for small lymphocytic lymphoma (SLL) and follicular lymphoma (FL) were voluntarily withdrawn by the manufacturer (Gilead Sciences, Inc.) after post-approval studies demonstrated increased mortality among treated patients [22,23]. Idelalisib currently carries a boxed warning outlining risks such as severe hepatotoxicity, infections, diarrhea/colitis, and pneumonitis.
Similarly, in 2022 the FDA revoked the indication of Duvelisib (7) for FL following evidence of increased fatal and/or severe toxicities, including infections and gastrointestinal adverse events, also reflected in its boxed warning. The approvals for Umbralisib (9) and Copanlisib (6) were withdrawn in 2022 and 2023, respectively, as accumulating data indicated elevated mortality risk associated with their approved uses. Despite these regulatory setbacks, PI3K inhibitors continue to be evaluated in clinical trials for new therapeutic indications, employing modified dosing schedules or novel combination regimens. This continued clinical interest underscores the therapeutic relevance of modulating PI3K signaling in oncology [22,23].
Although promising antitumor activity has been observed in selected malignancies, the efficacy of PI3K inhibitors as monotherapies remains limited, largely due to compensatory activation of parallel or downstream signaling pathways that ultimately promote treatment resistance [24]. This challenge has stimulated growing interest in combining PI3K inhibitors with other anticancer agents, as well as in the rational design of multitarget PI3K inhibitors capable of simultaneously modulating complementary molecular pathways [25,26]. Such strategies aim to enhance therapeutic efficacy, suppress adaptive resistance mechanisms, and broaden the clinical potential of PI3K-targeted therapies. In this context, a promising alternative that has been explored is the concomitant inhibition of PI3K and histone deacetylase, since the regulation of histone and non-histone protein acetylation levels modulates cellular events that synergize with the modulation of the PI3K signalling pathway. Studies have shown that PI3K inhibition significantly increases the cytotoxicity of HDAC inhibitors in lung cancer and chronic myeloid leukemia cells, indicating that dual inhibition of these two targets may be very effective [27,28].

1.2. Histone Deacetylases (HDAC)

Histone deacetylases (HDACs) represent one of the most extensively investigated classes of epigenetic regulators in oncology. These enzymes exert fundamental roles in transcriptional control and gene expression by modulating chromatin compaction and protein acetylation status, thereby influencing key cellular processes such as proliferation, differentiation, migration, and apoptosis [29,30,31]. The human HDAC family comprises 18 isoforms, grouped into four classes based on sequence homology, domain architecture, and cofactor dependency. Classes I (HDAC1, HDAC2, HDAC3, and HDAC8), IIa (HDAC4, HDAC5, HDAC7, and HDAC9), IIb (HDAC6 and HDAC10), and IV (HDAC11) constitute the zinc-dependent HDACs, whereas class III (sirtuins) are nicotinamide adenine dinucleotide (NAD+)-dependent deacylases [32]. HDACs catalyze the removal of acetyl groups from ε-N-lysine residues of histone and non-histone proteins, thereby regulating chromatin accessibility and diverse acetylation-dependent signaling pathways. Overexpression or dysregulation of specific HDAC isoforms has been implicated in the initiation and progression of multiple cancer types, reinforcing their therapeutic relevance as molecular targets for anticancer drug development [33].
To date, six histone deacetylase inhibitors (HDACis) have been approved for clinical use in humans. Five of these agents—vorinostat (11), romidepsin (12), belinostat (13), panobinostat (14), and tucidinostat (15)—are indicated for oncological applications, particularly hematological malignancies [34,35,36,37,38]. In 2024, givinostat (16, Figure 3) received FDA approval for the treatment of Duchenne muscular dystrophy, becoming the first HDAC inhibitor authorized for a non-oncological indication, thereby expanding the therapeutic landscape of this drug class [39].
Approved HDAC inhibitors (HDACis) continue to be investigated in clinical trials for additional therapeutic indications, and numerous next-generation inhibitors remain under active preclinical and clinical development [40]. Despite their validated clinical efficacy in hematological malignancies, the utility of HDACis as monotherapies is limited, particularly in the context of solid tumors. Several factors contribute to this reduced effectiveness. Solid tumors typically consist of more differentiated cell populations that display diminished sensitivity to epigenetic modulation. Moreover, HDACi monotherapy often triggers compensatory activation of alternative pro-survival and proliferative signaling pathways, including the PI3K pathway, ultimately promoting therapeutic resistance [41,42,43].
These observations reinforce the rationale for combinatorial strategies or for the rational design of multitarget agents capable of concurrently inhibiting both HDACs and PI3Ks. Such dual-modulation approaches may enhance antitumor efficacy, overcome adaptive resistance mechanisms, and broaden the clinical applicability of HDAC-based therapies.

2. PI3K and HDAC Signalling Pathway Inhibition

One of the earliest demonstrations of the therapeutic advantage of concomitant PI3K and HDAC inhibition was reported by Ellis et al., 2013, who described a pronounced synergistic effect arising from the combined administration of panobinostat (14, a pan-HDAC inhibitor) and BEZ235 (17, a dual PI3K/mTOR inhibitor) (Figure 4) [44]. In in vivo experiments conducted in male SCID mice bearing subcutaneous PC-3 or PC3-AR prostate tumor xenografts, the combination of compounds 14 and 17 produced a significantly greater reduction in tumor volume than either agent administered as monotherapy.
Mechanistic studies revealed that the dual-drug regimen induced heightened intratumoral DNA damage while concurrently decreasing DNA repair capacity. Furthermore, the combination led to a marked reduction in phosphorylated protein kinase B (p-AKT) levels—consistent with PI3K pathway suppression—thereby impairing a critical survival signaling axis.
Collectively, these findings demonstrated in animal models that dual PI3K/HDAC pathway blockade can produce robust synergistic antitumor activity and provided strong preclinical evidence supporting the development of combination-based therapeutic strategies for the treatment of prostate cancer in animal models [44].
In a related study, Piao et al. (2016) evaluated the therapeutic potential of combining BEZ235 (17) with trichostatin A (18), a prototypical pan-HDAC inhibitor, for the treatment of lung cancer (Figure 4) [26]. The authors demonstrated that the combination exerted a marked synergistic effect in non-small-cell lung cancer (NSCLC) cell lines (A549 and H460), resulting in enhanced inhibition of cell proliferation, induction of apoptosis, and suppression of tumor growth and metastatic dissemination in vivo [26].
Building upon these findings, the development of multitarget HDAC/PI3K inhibitors has gained substantial prominence in both the scientific and patent literature, with several candidates currently advancing through preclinical and clinical evaluation. To provide a comprehensive and updated overview of the state of the art in dual HDAC–PI3K modulation, we conducted a systematic search in the Scopus and Cortellis databases, as well as in clinical trial registries maintained by regulatory agencies. The search employed the keywords “HDAC” and “PI3K Dual Inhibitor” and covered the period from 2015 to 2025.
This strategy identified 72 scientific articles and 81 patents. From these, nine entries were selected based on the criteria of (i) reporting compounds with confirmed multitarget mechanisms involving both HDAC and PI3K inhibition, and (ii) having documented progression into preclinical or clinical development. These inhibitors are summarized and discussed in detail in the following sections.

3. Multitarget PI3K/HDAC Inhibitors in Clinical Phase

The first PI3K/HDAC multitarget inhibitor to advance into clinical evaluation was fimepinostat (CUDC-907, 21). Developed by Curis, this morpholinopyrimidine derivative represents the earliest dual HDAC–PI3K inhibitor to receive FDA Fast Track designation (2018) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [45]. The design of CUDC-907 (21) was guided by a molecular hybridization strategy that combined key pharmacophoric elements of quisinostat (JNJ-26481585, 20), a potent pan-HDAC inhibitor, and pictilisib (CUDC-0941, 19), a pan-PI3K inhibitor (Figure 5) [46].
The hydroxamic acid moiety—an essential zinc-binding group (ZBG) responsible for chelating the catalytic Zn2+ ion within the HDAC active site—was retained, along with the pyrimidine linker that properly positions the molecule within the HDAC catalytic channel, as supported by co-crystal structural analyses (Figure 6). Within the solvent-exposed region of the HDAC binding pocket, structural space permitted incorporation of the morpholinopyrimidine fragment, which functions as the hinge-binding pharmacophore necessary for engagement with the PI3K catalytic domain. Additionally, the 2-methoxypyridine group was added to enable complementary interactions at the kinase affinity pocket, contributing to high-affinity PI3K inhibition (Figure 6) [47,48,49].
Table 1 summarizes the biochemical potency data for fimepinostat (CUDC-90, 21) and its precursor prototypes, revealing IC50 values in the low-nanomolar range across both HDAC and PI3K targets [46,47,48]. Compound 21 exhibited robust antiproliferative activity in a broad panel of cancer cell lines, including those derived from solid tumors and hematologic malignancies, consistently outperforming the effects of isolated HDAC or PI3K inhibition as well as their combination as separate agents.
Mechanistically, treatment with CUDC-907 induced marked increases in acetylated tubulin, acetylated histone H3, p53, and acetylated p21—biochemical hallmarks of effective HDAC inhibition—alongside a significant reduction in phosphorylated AKT levels, confirming suppression of PI3K/AKT pathway signaling [46,50]. These dual pharmacodynamic signatures support the proposed multitarget mechanism of action and underscore the enhanced biological efficacy afforded by simultaneous HDAC and PI3K modulation.
Fimepinostat (21) remains under active clinical investigation for both solid tumors and hematologic malignancies, as well as for emerging non-oncological indications (Table 2). Notably, results from a phase I clinical trial (NCT01742988) in patients with lymphoma demonstrated that CUDC-907 (21) was well tolerated, with no dose-limiting toxicities or serious adverse events reported at the evaluated dose levels. Based on these findings, the FDA granted orphan drug designation to fimepinostat in 2018 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and for nuclear protein in testis (NUT) midline carcinoma [51,52]. These regulatory designations underscore the therapeutic promise of dual HDAC–PI3K inhibition and support continued clinical development across diverse disease settings.
Ifupinostat (BEBT-908, 22) is a structural analog of fimepinostat (21) originally discovered by Curis and subsequently licensed to Guangzhou BeBetter Medicine Technology Company. In July 2025, it received conditional approval from the China Food and Drug Administration (CFDA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who had failed at least two prior systemic therapies. With this authorization, ifupinostat became the first dual HDAC/PI3K inhibitor to obtain marketing approval in any country (Figure 7) [53].
Although detailed enzymatic potency data for ifupinostat (22) against HDAC and PI3K isoforms have not yet been disclosed, the company’s regulatory communication indicates that the compound exhibits a dual inhibitory mechanism targeting HDACs and PI3Kα, and has shown substantial antitumor activity in lymphoma models [54]. In a phase IIb clinical trial (NCT06074107) supporting its conditional approval, ifupinostat achieved an overall response rate (ORR) of 54.6% and a median overall survival (OS) of 8.8 months—nearly double that observed with standard first-line therapies.
Safety outcomes reported in the same study demonstrated that most hematologic adverse events were reversible and occurred without major complications such as severe bleeding or treatment-related mortality. Furthermore, non-hematologic toxicities were less frequent and generally milder compared with those associated with existing approved therapies for this indication. Ifupinostat (22) remains under active clinical investigation for R/R DLBCL, including combination regimens with additional chemotherapeutic agents (Table 2) [52], further supporting its potential as a next-generation multitarget therapeutic agent.

4. Multitarget PI3K/HDAC Inhibitors in Pre-Clinical Phase

Based on the literature search conducted for this review, eight dual HDAC/PI3K inhibitors currently supported by preclinical data were identified. These compounds will be discussed in the following sections according to the nature of their zinc-binding group (ZBG), a key structural determinant of HDAC inhibitory activity. Accordingly, the identified molecules are categorized into two major classes: hydroxamic acids and o-aminobenzamides.

4.1. Multitarget PI3K/HDAC Inhibitors Bearing Hydroxamic Acid Group

Inspired by the promising therapeutic profile of fimepinostat (21), Chen et al., 2016 [55], designed a series of structural analogues incorporating the morpholinopurine scaffold. This medicinal chemistry optimization effort led to the identification of compound 23, a dual HDAC/PI3K inhibitor that exhibited enhanced potency against both targets compared with the parent compound (Figure 8).
In vitro studies demonstrated that compound 23 effectively inhibited the phosphorylation of key components of the PI3K signaling axis, including PI3K, mTOR, and AKT, while simultaneously increasing acetylation levels of histone H3 and α-tubulin—pharmacodynamic hallmarks consistent with HDAC inhibition. These findings confirm the multitarget inhibitory profile of this molecule. However, when evaluated in vivo using the MV4-11 xenograft model in NOD/SCID mice, compound 23 exhibited the weakest antiproliferative activity within its series and displayed poor aqueous solubility coupled with toxicity concerns. These limitations indicate that further structural optimization is warranted to enhance solubility and mitigate potential toxicophoric liabilities [55].
In a subsequent study, Chen et al. (2018) [56] designed and synthesized PI3K/HDAC multitarget inhibitors incorporating the morpholinopyrimidine scaffold for the treatment of hepatocellular carcinoma (HCC). Among the synthesized derivatives, compound 25 emerged as the lead prototype based on superior in vitro potency and in vivo efficacy. The rational design of this series was informed by prior structure–activity relationship (SAR) studies of purine-based PI3K/mTOR inhibitors (24). Guided by these insights, targeted structural modifications were introduced to integrate pharmacophoric elements necessary for HDAC inhibition—specifically an appropriate linker region and a zinc-binding group (ZBG)—yielding hybrid molecules optimized for dual pathway modulation (Figure 9).
Structural modifications introduced into the PI3K-interactive region of compound 25 preserved high potency against PI3Kα; however, a ~5-fold reduction in mTOR inhibitory activity was observed relative to the parent compound. The HDAC activity profile was optimized with a six-carbon aliphatic linker, which afforded low-nanomolar potency against HDAC isoforms 1, 2, 3, 6, and 10. Compound 25 demonstrated the ability to modulate both pathways, as evidenced by increased acetylation of histone H3 and α-tubulin, along with reduced phosphorylation of Akt, across multiple cancer cell lines (PC-3, MCF-7, and HepG2). Dual-pathway modulation was further confirmed in vivo using MV4-11 and HepG2 xenograft models in NCr mice.
Importantly, compound 25 exhibited significant oral efficacy as a single agent in hepatocellular carcinoma (HCC) and metastatic breast cancer (4T1) models, coupled with favorable drug-like properties. These features supported its nomination as a promising candidate for further development, either as monotherapy or in combination regimens, with potential therapeutic applications in HCC, acute myeloid leukemia (AML), and non-Hodgkin lymphomas [56].
In 2019, Zhang et al. sought to circumvent the recurrent use of the morpholinopyrimidine scaffold by exploring a 4-methylquinazoline core for the design of dual PI3K/HDAC inhibitors [57]. Design strategy was based on the hybridization of compound 26, previously identified as PI3K inhibitor by their group, with pharmacophoric elements characteristic of HDACis such as compounds 11 and 20 (Figure 10). Structure–activity relationship (SAR) studies were constructed by systematically modifying the linker segment attached to the hydroxamic acid zinc-binding group and by introducing substitutions on the 2-methoxypyridine ring to fine-tune PI3K activity.
Among the compounds synthesized in this series, compound 27 was selected as the lead prototype for further development due to its robust inhibitory potency against both PI3K and HDAC targets, its favorable kinase selectivity profile, and its strong antiproliferative activity across a range of cancer cell lines derived from solid tumors and hematologic malignancies (e.g., THP-1, MCF-7, U87). The compound also exhibited an acceptable preliminary safety profile. Despite less favorable pharmacokinetic characteristics—including low oral bioavailability and rapid systemic clearance, attributed primarily to metabolic instability of the hydroxamic acid group—compound 27 nevertheless demonstrated in vivo efficacy in an HCT116 human colon cancer xenograft model. Dual-pathway engagement was confirmed by increased acetylation of histone H3 and decreased phosphorylated AKT levels in tumor tissues [57].
In 2020, Thakur et al. reported an extensive series of dual PI3K/HDAC inhibitors featuring quinazoline or quinazolinone scaffolds as central cores, strategically integrating the essential pharmacophoric elements required for interaction with both PI3K and HDAC (Figure 11). The design strategy drew inspiration from structural features of idelalisib (5) and vorinostat (11), with systematic modifications introduced into the linker region attached to the hydroxamic acid zinc-binding group, as well as the PI3K hinge-binding fragment. The overarching aim was to generate selective and potent dual inhibitors capable of overcoming limitations associated with non-selective pan-inhibition of both HDACs and PI3Ks [58].
Extensive SAR investigations led to the identification of several potent and selective dual PI3K/HDAC inhibitors incorporating a purine moiety as the hinge-binding element, along with a linker connected to a hydroxamic acid zinc-binding group. Among these derivatives, the benzylamine-containing linker region emerged as a key structural determinant conferring preferential selectivity toward HDAC6. Despite displaying strong enzymatic inhibition profiles, this first-generation series did not exhibit satisfactory antiproliferative activity across the human tumor cell lines of the NCI-60 panel, which the authors attributed primarily to poor cellular permeability [58].
To address this limitation, a second-generation series was designed in which the purine hinge binder was replaced with a substituted aminopyrimidine fragment, with the aim of improving passive permeability and overall cell penetration. This optimization effort culminated in the identification of compound 28 as the lead prototype. Compound 28 demonstrated pronounced selectivity for HDAC6 within the HDAC family and a pan-PI3K inhibition profile, exhibiting low-nanomolar potency across both target classes. Notably, 28 showed excellent antiproliferative activity in multiple tumor cell lines and induced robust necrotic responses in AML models. In addition, the compound displayed improved metabolic stability and acceptable in vivo pharmacokinetic properties, supporting its advancement into ongoing lead optimization efforts [58].
Selective inhibition of HDAC6 in PI3K/HDAC MTDL development was the first strategy to surpass pan-HDAC inhibition associated problems. HDAC6 is quite different from the other HDAC isoenzymes, mainly due its exclusive cytoplasmic cellular location, which is associated with the modulation of non-histone proteins that are involved in cancer process (e. g., tubulin, heat shock protein 90, actin, etc.) [59,60]. Additionally, HDAC6 selective modulation may cause less toxicity since its knockout appears to not cause embryonic lethality in animal models [61].
In a complementary approach to identify selective dual PI3K/HDAC inhibitors, Li et al., 2022, designed and synthesized a series of molecules engineered to selectively inhibit PI3Kδ and HDAC6 isoforms [62]. The design strategy was grounded in conformational analogues of structures 29 and 30, themselves derived from the selective PI3Kδ inhibitor idelalisib (5), onto which HDAC-directed pharmacophores were strategically introduced (Figure 12). The decision to focus on HDAC6 selectivity stemmed from several considerations: (i) HDAC6 silencing is associated with a lower risk of lethality compared to inhibition of class I HDACs; (ii) HDAC6 regulates deacetylation of multiple non-histone substrates involved in tumor initiation, migration, and metastasis; and (iii) HDAC6 participates in immunomodulatory processes within the tumor microenvironment [33,59,63].
Similarly, targeted inhibition of PI3Kδ not only disrupts intrinsic tumor cell growth and metastatic progression, but also enhances antitumor immunity by modulating leukocyte function and tumor–immune interactions. This dual mechanism suggests a potentially synergistic therapeutic rationale for concurrent inhibition of PI3Kδ and HDAC6 isoforms [64,65].
Based on the SAR analysis, the authors observed that, with regard to PI3Kδ inhibition, a chlorine substituent at the R1 position conferred greater potency than fluorine. Furthermore, the 2,4-diaminopyrimidine-5-carbonitrile moiety proved to be a superior hinge-binding (HB) element compared to the purine scaffold originally employed [62]. In addition, methylene-aryl linkers and nitrogen-containing seven-membered spirocyclic spacers markedly enhanced both potency and selectivity toward HDAC6.
Within this optimized series, compound 31 demonstrated the most favorable enzymatic inhibition profile, exhibiting low-nanomolar potency across both PI3Kδ and HDAC6. The compound also displayed a strong selectivity index within the HDAC family (>18) and within the PI3K class (>13). In cell-based assays, compound 31 showed satisfactory antiproliferative activity across multiple tumor cell lines, with potencies ranging from the mid-nanomolar to low-micromolar range. Notably, in the T47D breast ductal carcinoma line, compound 31 outperformed the corresponding single-target PI3K and HDAC inhibitors by a substantial margin. The compound also exhibited acceptable cytotoxicity toward normal HUVEC cells, indicating a preliminary therapeutic window.
However, a preliminary pharmacokinetic (PK) assessment in Sprague-Dawley rats revealed unfavorable PK properties, including low oral absorption, a short half-life (0.46 h), and a clearance rate of 3.18 L/h/kg. These findings indicate the need for further structural optimization to enhance metabolic stability and systemic exposure [62].

4.2. Multitarget PI3K/HDAC Inhibitors Bearing o-Aminobenzamide Group

Despite the fact that most clinically approved HDAC inhibitors are hydroxamic acids, their therapeutic use is frequently limited by dose-dependent toxicities, including risks of genotoxicity and severe adverse events associated with pan-HDAC inhibition. Moreover, hydroxamate-based inhibitors exhibit suboptimal pharmacokinetic behavior due to rapid metabolic degradation and narrow therapeutic indices [66]. These limitations have driven efforts to identify alternative zinc-binding groups (ZBGs) with improved safety and pharmacological profiles. Notably, the recent approval of tucidinostat (15) by the CFDA has intensified interest in o-aminobenzamide-based HDAC inhibitors, a scaffold exemplified by entinostat (34), which is currently undergoing phase II/III clinical evaluation for solid tumors (NCT02115282) and hematologic malignancies (NCT03179930), and which received CFDA approval in 2024 for the treatment of advanced or metastatic breast cancer (NCT03538171).
Seeking alternatives to hydroxamate ZBGs for dual PI3K/HDAC modulation, Deng et al. (2023) designed a novel series of multitarget inhibitors incorporating a benzamide group as the zinc-binding pharmacophore [67]. Their strategy was guided by structural analyses of the PI3K inhibitor PC (33), which contains a morpholinotriazine core, and by benzamide-based HDAC inhibitors such as CI-994 (32) and entinostat (34). Through a rational molecular hybridization approach, the authors generated hybrid molecules that preserved the essential pharmacophoric features required for activity at each target: (i) a morpholine moiety to anchor within the PI3K hinge region, (ii) a urea fragment positioned to establish hydrogen-bond interactions at the PI3K affinity site, and (iii) a benzamide ZBG capable of forming the characteristic bidentate coordination with the catalytic zinc ion in the HDAC active site via its carbonyl oxygen and aniline nitrogen (Figure 13) [67].
Following extensive SAR evaluation, compound 35 emerged as the lead molecule, exhibiting potent multitarget activity against class I HDAC isoforms (HDAC1 IC50 = 305.2 nM, HDAC2 IC50 = 443.7 nM, and HDAC3 IC50 = 24.5 nM) as well as broad PI3K inhibition (PI3Kα IC50 = 20.3 nM, PI3Kβ IC50 = 29.5 nM, PI3Kδ IC50 = 205.7 nM, and PI3Kγ IC50 = 95.4 nM). In cell-based antiproliferative assays, compound 35 demonstrated low-micromolar activity across multiple tumor cell lines, including MM1.S (multiple myeloma), Jeko-1 (mantle cell lymphoma), HL-60 (acute promyelocytic leukemia), and MDA-MB-231 (triple-negative breast cancer). Notably, 35 was more potent than the reference HDAC inhibitor CI-994 (29) and the PI3K inhibitor PC (28), and displayed no detectable cytotoxicity in normal human liver HL-7702 cells.
Dual-target engagement by compound 35 was confirmed through its ability to downregulate phosphorylated AKT while increasing acetylated histone H3 levels. The absence of tubulin acetylation indicated selective inhibition of class I HDACs rather than HDAC6. Moreover, compound 35 induced apoptosis in Jeko-1 cells—a response not observed with either reference inhibitor 32 or 33—highlighting the functional importance of simultaneous HDAC and PI3K inhibition [67].
To identify new dual PI3K/HDAC inhibitors for the treatment of acute myeloid leukemia (AML), Zhang et al., 2024, designed a series of 4-methylquinazoline derivatives incorporating a benzamide zinc-binding group (ZBG) [68]. Their design strategy involved analyzing the binding mode of compound 36, a PI3K inhibitor featuring the 4-methylquinazoline scaffold. Structural modeling revealed that, in addition to establishing canonical interactions at the hinge region and affinity pocket, the C-8 position of the quinazoline ring was oriented toward the solvent-exposed region, providing an optimal site for structural extension (Figure 14) [68].
From the SAR analyses, compounds 37 and 38 emerged as the most promising dual inhibitors, exhibiting the strongest simultaneous enzymatic inhibition of PI3K and class I HDAC isoforms, along with the most potent antiproliferative activities across a broad panel of hematologic cancer cell lines. These included acute myeloid leukemia (AML) cell lines (MV4-11, NB4, HL-60), non-Hodgkin lymphoma (NHL) cell lines (DOHH2, Ramos, Raji), and mantle cell lymphoma (MCL) cells (Mino). In most of these models—particularly in MV4-11—compounds 37 and 38 demonstrated markedly superior antiproliferative activity relative to the reference HDAC inhibitors tucidinostat (15) and vorinostat (11).
Western blot and flow cytometry analyses confirmed effective dual-pathway engagement for both compounds, evidenced by reduced phosphorylated AKT levels and increased acetylated histone H3 in MV4-11 cells. These pharmacodynamic signatures validated the intended simultaneous PI3K and HDAC inhibition.
In vivo pharmacokinetic studies in ICR mice revealed that both 37 and 38 possessed a mean half-life of approximately 2.35 h. Although oral bioavailability remained low, the overall systemic exposure (AUC) following intravenous and oral administration was superior to that of comparable hydroxamate-based analogues, indicating improved metabolic stability.
Importantly, compounds 37 and 38 exhibited potent, dose-dependent antitumor activity in MV4-11 xenograft models in nude mice, further supporting their potential as viable candidates for continued preclinical development [68].

5. Summary and Outlook

The emergence of multitarget-directed ligands (MTDLs) has reshaped therapeutic strategies for multifactorial diseases, particularly in oncology, where conventional single-target approaches frequently fail to overcome the complexity and adaptability of tumor biology. This paradigm shift underscores the growing necessity for drug design methodologies capable of simultaneously modulating multiple signaling pathways implicated in cancer progression, thereby enhancing therapeutic efficacy while potentially mitigating toxicity and resistance mechanisms. Within this context, the dual modulation of epigenetic regulators and kinase-driven signaling cascades—most notably through concurrent inhibition of HDACs and PI3Ks—has gained increasing prominence as a rational and promising strategy for anticancer drug development.
The discovery of fimepinostat (CUDC-907, 21), the first-in-class PI3K/HDAC multitarget inhibitor to enter phase I/II clinical trials, catalyzed extensive research efforts aimed at producing next-generation dual modulators with diverse selectivity profiles and refined pharmacological properties. Although many of these compounds have demonstrated compelling biological activity in vitro and in vivo, challenges related to pharmacokinetics, pharmacodynamics, and safety—particularly those associated with hydroxamic acid zinc-binding groups—remain major obstacles to clinical translation.
Hydroxamates, despite their high-potency, are frequently limited by rapid metabolic clearance, poor oral bioavailability, and concerns regarding genotoxicity. The major factor that leads to mutagenicity caused by hydroxamic acids is a Lossen rearrangement, which converts a hydroxamate to its isocyanate derivative. This species is unstable and can react with nucleophiles such as DNA nucleophilic groups [66].
These limitations have driven a clear trend toward the exploration of alternative scaffolds capable of providing more selective, stable, and safer interactions with the HDAC catalytic zinc ion. The recent regulatory approvals of tucidinostat (15) and entinostat (34) by the CFDA have strengthened interest in ortho-aminobenzamide–based ZBGs as viable substitutes for hydroxamates, particularly considering their improved pharmacological tolerability and therapeutic potential in both solid and hematologic malignancies.
Collectively, the progress summarized in this review demonstrates that dual PI3K/HDAC inhibition remains a highly promising therapeutic avenue. Continued optimization of scaffold design, ZBG selection, and target selectivity holds substantial potential to yield next-generation multitarget agents capable of addressing unmet clinical needs in oncology.

Author Contributions

Writing—original draft preparation A.D.S.L. and L.M.L.; writing—review and editing A.D.S.L. and L.M.L. All authors have read and agreed to the published version of the manuscript.

Funding

The authors thank support from INCT-INOFAR (#465.249/2014-0 and #E-26/010.000090/2018), CNPq (#465.249/2014-0), FAPERJ (#SEI260003/001165/2020; #E-26/200.385/20230) and CAPES (Finance Code 001).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Giordano, S.; Petrelli, A. From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Curr. Med. Chem. 2008, 15, 422–432. [Google Scholar] [CrossRef]
  2. Hopkins, A.L. Network Pharmacology: The next Paradigm in Drug Discovery. Nat. Chem. Biol. 2008, 4, 682–690. [Google Scholar] [CrossRef] [PubMed]
  3. Medina-Franco, J.L.; Giulianotti, M.A.; Welmaker, G.S.; Houghten, R.A. Shifting from the Single to the Multitarget Paradigm in Drug Discovery. Drug Discov. Today 2013, 18, 495–501. [Google Scholar] [CrossRef]
  4. Fu, R.; Sun, Y.; Sheng, W.; Liao, D. Designing Multi-Targeted Agents: An Emerging Anticancer Drug Discovery Paradigm. Eur. J. Med. Chem. 2017, 136, 195–211. [Google Scholar] [CrossRef]
  5. Zhou, J.; Jiang, X.; He, S.; Jiang, H.; Feng, F.; Liu, W.; Qu, W.; Sun, H. Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. J. Med. Chem. 2019, 62, 8881–8914. [Google Scholar] [CrossRef] [PubMed]
  6. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. J. Med. Chem. 2005, 48, 6523–6543. [Google Scholar] [CrossRef]
  7. Yesilkanal, A.E.; Johnson, G.L.; Ramos, A.F.; Rosner, M.R. New Strategies for Targeting Kinase Networks in Cancer. J. Biol. Chem. 2021, 297, 101128. [Google Scholar] [CrossRef] [PubMed]
  8. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: Challenges and Opportunities in Drug Discovery. J. Med. Chem. 2014, 57, 7874–7887. [Google Scholar] [CrossRef]
  9. Costantino, L.; Barlocco, D. Designed Multiple Ligands: Basic Research vs Clinical Outcomes. Curr. Med. Chem. 2012, 19, 3353–3387. [Google Scholar] [CrossRef]
  10. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K Pathway As Drug Target in Human Cancer. J. Clin. Oncol. 2010, 28, 1075–1083. [Google Scholar] [CrossRef]
  11. Yang, J.; Nie, J.; Ma, X.; Wei, Y.; Peng, Y.; Wei, X. Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials. Mol. Cancer 2019, 18, 26. [Google Scholar] [CrossRef]
  12. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M.D. Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer. Annu. Rev. Cell Dev. Biol. 2001, 17, 615–675. [Google Scholar] [CrossRef] [PubMed]
  13. Thorpe, L.M.; Yuzugullu, H.; Zhao, J.J. PI3K in Cancer: Divergent Roles of Isoforms, Modes of Activation and Therapeutic Targeting. Nat. Rev. Cancer 2015, 15, 7–24. [Google Scholar] [CrossRef]
  14. Engelman, J.A. Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations. Nat. Rev. Cancer 2009, 9, 550–562. [Google Scholar] [CrossRef]
  15. Markham, A. Idelalisib: First Global Approval. Drugs 2014, 74, 1701–1707. [Google Scholar] [CrossRef] [PubMed]
  16. Markham, A. Copanlisib: First Global Approval. Drugs 2017, 77, 2057–2062. [Google Scholar] [CrossRef] [PubMed]
  17. Blair, H.A. Duvelisib: First Global Approval. Drugs 2018, 78, 1847–1853. [Google Scholar] [CrossRef]
  18. Markham, A. Alpelisib: First Global Approval. Drugs 2019, 79, 1249–1253. [Google Scholar] [CrossRef]
  19. Dhillon, S.; Keam, S.J. Umbralisib: First Approval. Drugs 2021, 81, 857–866. [Google Scholar] [CrossRef]
  20. Blair, H.A. Inavolisib: First Approval. Drugs 2025, 85, 271–278. [Google Scholar] [CrossRef]
  21. Skanland, S.S.; Brown, J.R. PI3K Inhibitors in Chronic Lymphocytic Leukemia: Where Do We Go from Here? Haematologica 2022, 108, 9–21. [Google Scholar] [CrossRef] [PubMed]
  22. Skånland, S.S.; Okkenhaug, K.; Davids, M.S. PI3K Inhibitors in Hematology: When One Door Closes…. Clin. Cancer Res. 2024, 30, 3667–3675. [Google Scholar] [CrossRef]
  23. Yu, M.; Chen, J.; Xu, Z.; Yang, B.; He, Q.; Luo, P.; Yan, H.; Yang, X. Development and Safety of PI3K Inhibitors in Cancer. Arch. Toxicol. 2023, 97, 635–650. [Google Scholar] [CrossRef]
  24. Wright, S.C.E.; Vasilevski, N.; Serra, V.; Rodon, J.; Eichhorn, P.J.A. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers 2021, 13, 1538. [Google Scholar] [CrossRef]
  25. Saini, K.S.; Loi, S.; de Azambuja, E.; Metzger-Filho, O.; Saini, M.L.; Ignatiadis, M.; Dancey, J.E.; Piccart-Gebhart, M.J. Targeting the PI3K/AKT/MTOR and Raf/MEK/ERK Pathways in the Treatment of Breast Cancer. Cancer Treat. Rev. 2013, 39, 935–946. [Google Scholar] [CrossRef]
  26. Piao, J.; Chen, L.; Quan, T.; Li, L.; Quan, C.; Piao, Y.; Jin, T.; Lin, Z. Superior Efficacy of Co-Treatment with the Dual PI3K/MTOR Inhibitor BEZ235 and Histone Deacetylase Inhibitor Trichostatin A against NSCLC. Oncotarget 2016, 7, 60169–60180. [Google Scholar] [CrossRef] [PubMed]
  27. Ozaki, K.; Kosugi, M.; Baba, N.; Fujio, K.; Sakamoto, T.; Kimura, S.; Tanimura, S.; Kohno, M. Blockade of the ERK or PI3K–Akt Signaling Pathway Enhances the Cytotoxicity of Histone Deacetylase Inhibitors in Tumor Cells Resistant to Gefitinib or Imatinib. Biochem. Biophys. Res. Commun. 2010, 391, 1610–1615. [Google Scholar] [CrossRef]
  28. Wozniak, M.B.; Villuendas, R.; Bischoff, J.R.; Aparicio, C.B.; Martinez Leal, J.F.; de La Cueva, P.; Rodriguez, M.E.; Herreros, B.; Martin-Perez, D.; Longo, M.I.; et al. Vorinostat Interferes with the Signaling Transduction Pathway of T-Cell Receptor and Synergizes with Phosphoinositide-3 Kinase Inhibitors in Cutaneous T-Cell Lymphoma. Haematologica 2010, 95, 613–621. [Google Scholar] [CrossRef] [PubMed]
  29. Falkenberg, K.J.; Johnstone, R.W. Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders. Nat. Rev. Drug. Discov. 2014, 13, 673–691. [Google Scholar] [CrossRef]
  30. Reichert, N.; Choukrallah, M.-A.; Matthias, P. Multiple Roles of Class I HDACs in Proliferation, Differentiation, and Development. Cell. Mol. Life Sci. 2012, 69, 2173–2187. [Google Scholar] [CrossRef]
  31. Minucci, S.; Pelicci, P.G. Histone Deacetylase Inhibitors and the Promise of Epigenetic (and More) Treatments for Cancer. Nat. Rev. Cancer 2006, 6, 38–51. [Google Scholar] [CrossRef] [PubMed]
  32. Seto, E.; Yoshida, M. Erasers of Histone Acetylation: The Histone Deacetylase Enzymes. Cold Spring Harb. Perspect. Biol. 2014, 6, a018713. [Google Scholar] [CrossRef]
  33. Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC Family: What Are the Cancer Relevant Targets? Cancer Lett. 2009, 277, 8–21. [Google Scholar] [CrossRef]
  34. Marks, P.A.; Breslow, R. Dimethyl Sulfoxide to Vorinostat: Development of This Histone Deacetylase Inhibitor as an Anticancer Drug. Nat. Biotechnol. 2007, 25, 84–90. [Google Scholar] [CrossRef]
  35. Yang, L.P.H. Romidepsin. Drugs 2011, 71, 1469–1480. [Google Scholar] [CrossRef]
  36. Poole, R.M. Belinostat: First Global Approval. Drugs 2014, 74, 1543–1554. [Google Scholar] [CrossRef]
  37. Garnock-Jones, K.P. Panobinostat: First Global Approval. Drugs 2015, 75, 695–704. [Google Scholar] [CrossRef] [PubMed]
  38. Lu, X.; Ning, Z.; Li, Z.; Cao, H.; Wang, X. Development of Chidamide for Peripheral T-Cell Lymphoma, the First Orphan Drug Approved in China. Intractable Rare Dis. Res. 2016, 5, 185–191. [Google Scholar] [CrossRef]
  39. Lamb, Y.N. Givinostat: First Approval. Drugs 2024, 84, 849–856. [Google Scholar] [CrossRef] [PubMed]
  40. Bondarev, A.D.; Attwood, M.M.; Jonsson, J.; Chubarev, V.N.; Tarasov, V.V.; Schiöth, H.B. Recent Developments of HDAC Inhibitors: Emerging Indications and Novel Molecules. Br. J. Clin. Pharmacol. 2021, 87, 4577–4597. [Google Scholar] [CrossRef]
  41. Slingerland, M.; Guchelaar, H.-J.; Gelderblom, H. Histone Deacetylase Inhibitors. Anticancer Drugs 2014, 25, 140–149. [Google Scholar] [CrossRef]
  42. Mercurio, C.; Minucci, S.; Pelicci, P.G. Histone Deacetylases and Epigenetic Therapies of Hematological Malignancies. Pharmacol. Res. 2010, 62, 18–34. [Google Scholar] [CrossRef] [PubMed]
  43. Zeng, H.; Qu, J.; Jin, N.; Xu, J.; Lin, C.; Chen, Y.; Yang, X.; He, X.; Tang, S.; Lan, X.; et al. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell 2016, 30, 459–473. [Google Scholar] [CrossRef]
  44. Ellis, L.; Ku, S.; Ramakrishnan, S.; Lasorsa, E.; Azabdaftari, G.; Godoy, A.; Pili, R. Combinatorial Antitumor Effect of HDACs and the PI3K-Akt-MTOR Pathway Inhibition in a Pten Deficient Model of Prostate Cancer. Oncotarget 2013, 4, 2225–2236. [Google Scholar] [CrossRef]
  45. Qiao, X.; Ma, J.; Knight, T.; Su, Y.; Edwards, H.; Polin, L.; Li, J.; Kushner, J.; Dzinic, S.H.; White, K.; et al. The Combination of CUDC-907 and Gilteritinib Shows Promising in Vitro and in Vivo Antileukemic Activity against FLT3-ITD AML. Blood Cancer J. 2021, 11, 111. [Google Scholar] [CrossRef]
  46. Qian, C.; Lai, C.-J.; Bao, R.; Wang, D.-G.; Wang, J.; Xu, G.-X.; Atoyan, R.; Qu, H.; Yin, L.; Samson, M.; et al. Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling. Clin. Cancer Res. 2012, 18, 4104–4113. [Google Scholar] [CrossRef]
  47. Arts, J.; King, P.; Marin, A.; Floren, W.; Belin, A.; Janssen, L.; Pilatte, I.; Roux, B.; Decrane, L.; Gilissen, R.; et al. JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clin. Cancer Res. 2009, 15, 6841–6851. [Google Scholar] [CrossRef]
  48. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.; et al. The Identification of 2-(1H-Indazol-4-Yl)-6-(4-Methanesulfonyl-Piperazin-1-Ylmethyl)-4-Morpholin-4-Yl-Thieno[3,2-d]Pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. J. Med. Chem. 2008, 51, 5522–5532. [Google Scholar] [CrossRef] [PubMed]
  49. Andrs, M.; Korabecny, J.; Jun, D.; Hodny, Z.; Bartek, J.; Kuca, K. Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring. J. Med. Chem. 2015, 58, 41–71. [Google Scholar] [CrossRef] [PubMed]
  50. Turke, A.B.; Song, Y.; Costa, C.; Cook, R.; Arteaga, C.L.; Asara, J.M.; Engelman, J.A. MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors. Cancer Res. 2012, 72, 3228–3237. [Google Scholar] [CrossRef]
  51. Younes, A.; Berdeja, J.G.; Patel, M.R.; Flinn, I.; Gerecitano, J.F.; Neelapu, S.S.; Kelly, K.R.; Copeland, A.R.; Akins, A.; Clancy, M.S.; et al. Safety, Tolerability, and Preliminary Activity of CUDC-907, a First-in-Class, Oral, Dual Inhibitor of HDAC and PI3K, in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma: An Open-Label, Dose-Escalation, Phase 1 Trial. Lancet Oncol. 2016, 17, 622–631. [Google Scholar] [CrossRef]
  52. Landsburg, D.J.; Barta, S.K.; Ramchandren, R.; Batlevi, C.; Iyer, S.; Kelly, K.; Micallef, I.N.; Smith, S.M.; Stevens, D.A.; Alvarez, M.; et al. Fimepinostat (CUDC-907) in Patients with Relapsed/Refractory Diffuse Large B Cell and High-grade B-cell Lymphoma: Report of a Phase 2 Trial and Exploratory Biomarker Analyses. Br. J. Haematol. 2021, 195, 201–209. [Google Scholar] [CrossRef]
  53. Fan, F.; Liu, P.; Bao, R.; Chen, J.; Zhou, M.; Mo, Z.; Ma, Y.; Liu, H.; Zhou, Y.; Cai, X.; et al. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. Cancer Res. 2021, 81, 6233–6245. [Google Scholar] [CrossRef]
  54. BEBT-908, the World’s First (First-in-Class) Dual-Target Anti-Cancer Drug, Was Approved for Marketing by the State Food and Drug Administration. Available online: https://www.bebettermed.com/#pipeline (accessed on 28 December 2025).
  55. Chen, Y.; Wang, X.; Xiang, W.; He, L.; Tang, M.; Wang, F.; Wang, T.; Yang, Z.; Yi, Y.; Wang, H.; et al. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. J. Med. Chem. 2016, 59, 5488–5504. [Google Scholar] [CrossRef] [PubMed]
  56. Chen, D.; Soh, C.K.; Goh, W.H.; Wang, H. Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. J. Med. Chem. 2018, 61, 1552–1575. [Google Scholar] [CrossRef]
  57. Zhang, K.; Lai, F.; Lin, S.; Ji, M.; Zhang, J.; Zhang, Y.; Jin, J.; Fu, R.; Wu, D.; Tian, H.; et al. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. J. Med. Chem. 2019, 62, 6992–7014. [Google Scholar] [CrossRef] [PubMed]
  58. Thakur, A.; Tawa, G.J.; Henderson, M.J.; Danchik, C.; Liu, S.; Shah, P.; Wang, A.Q.; Dunn, G.; Kabir, M.; Padilha, E.C.; et al. Design, Synthesis, and Biological Evaluation of Quinazolin-4-One-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J. Med. Chem. 2020, 63, 4256–4292. [Google Scholar] [CrossRef]
  59. Aldana-Masangkay, G.I.; Sakamoto, K.M. The Role of HDAC6 in Cancer. BioMed Res. Int. 2011, 2011, 875824. [Google Scholar] [CrossRef]
  60. Li, Y.; Shin, D.; Kwon, S.H. Histone Deacetylase 6 Plays a Role as a Distinct Regulator of Diverse Cellular Processes. FEBS J. 2013, 280, 775–793. [Google Scholar] [CrossRef] [PubMed]
  61. Kalin, J.H.; Bergman, J.A. Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors. J. Med. Chem. 2013, 56, 6297–6313. [Google Scholar] [CrossRef]
  62. Li, Z.; Zhao, C.; He, G.; Wang, Y.; Wang, Y.; Ma, X. Identification of PI3K/HDAC Dual-Targeted Inhibitors with Subtype Selectivity as Potential Therapeutic Agents against Solid Tumors: Building HDAC6 Potency in a Quinazolinone-Based PI3Kδ-Selective Template. Bioorg. Med. Chem. 2022, 73, 117028. [Google Scholar] [CrossRef]
  63. Zhang, Y.; Kwon, S.; Yamaguchi, T.; Cubizolles, F.; Rousseaux, S.; Kneissel, M.; Cao, C.; Li, N.; Cheng, H.-L.; Chua, K.; et al. Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally. Mol. Cell. Biol. 2008, 28, 1688–1701. [Google Scholar] [CrossRef] [PubMed]
  64. Ali, K.; Soond, D.R.; Piñeiro, R.; Hagemann, T.; Pearce, W.; Lim, E.L.; Bouabe, H.; Scudamore, C.L.; Hancox, T.; Maecker, H.; et al. Inactivation of PI(3)K P110δ Breaks Regulatory T-Cell-Mediated Immune Tolerance to Cancer. Nature 2014, 510, 407–411. [Google Scholar] [CrossRef] [PubMed]
  65. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nat. Rev. Drug. Discov. 2005, 4, 988–1004. [Google Scholar] [CrossRef] [PubMed]
  66. Shen, S.; Kozikowski, A.P. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget? ChemMedChem 2016, 11, 15–21. [Google Scholar] [CrossRef]
  67. Deng, J.; Hou, B.; Hou, X.; Chen, Y.; Zhang, T.; Chen, H.; Wang, Y.; Li, X. Discovery of Benzamide-Based PI3K/HDAC Dual Inhibitors with Marked pro-Apoptosis Activity in Lymphoma Cells. Eur. J. Med. Chem. 2023, 262, 115915. [Google Scholar] [CrossRef]
  68. Zhang, K.; Huang, R.; Ji, M.; Lin, S.; Lai, F.; Wu, D.; Tian, H.; Bi, J.; Peng, S.; Hu, J.; et al. Rational Design and Optimization of Novel 4-Methyl Quinazoline Derivatives as PI3K/HDAC Dual Inhibitors with Benzamide as Zinc Binding Moiety for the Treatment of Acute Myeloid Leukemia. Eur. J. Med. Chem. 2024, 264, 116015. [Google Scholar] [CrossRef]
Pharmaceuticals 19 00130 g001
Figure 1. Chemical structures of FDA-approved multitarget inhibitors 1 and 2 and clinical candidates 3 and 4.
Figure 1. Chemical structures of FDA-approved multitarget inhibitors 1 and 2 and clinical candidates 3 and 4.
Pharmaceuticals 19 00130 g001
Pharmaceuticals 19 00130 g002
Figure 2. Chemical structures of PI3K inhibitors approved for clinical use. CLL; chronic lymphocytic leukemia, SLL; small lymphocytic leukemia, FL; follicular lymphoma, MZL; marginal zone lymphoma, BC; breast cancer, FDA; U.S. Food and Drug Administration, EMA; European Medicines Agency [15,16,17,18,19,20].
Figure 2. Chemical structures of PI3K inhibitors approved for clinical use. CLL; chronic lymphocytic leukemia, SLL; small lymphocytic leukemia, FL; follicular lymphoma, MZL; marginal zone lymphoma, BC; breast cancer, FDA; U.S. Food and Drug Administration, EMA; European Medicines Agency [15,16,17,18,19,20].
Pharmaceuticals 19 00130 g002
Pharmaceuticals 19 00130 g003
Figure 3. Chemical structures of HDAC inhibitors approved for clinical use. BC, breast cancer; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; DMD, Duchenne muscular dystrophy; MM, multiple myeloma; PTCL, peripheral T-cell lymphoma [34,35,36,37,38,39].
Figure 3. Chemical structures of HDAC inhibitors approved for clinical use. BC, breast cancer; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; DMD, Duchenne muscular dystrophy; MM, multiple myeloma; PTCL, peripheral T-cell lymphoma [34,35,36,37,38,39].
Pharmaceuticals 19 00130 g003
Pharmaceuticals 19 00130 g004
Figure 4. Chemical structures of compounds 17 and 18.
Figure 4. Chemical structures of compounds 17 and 18.
Pharmaceuticals 19 00130 g004
Pharmaceuticals 19 00130 g005
Figure 5. Rational design of fimepinostat (21).
Figure 5. Rational design of fimepinostat (21).
Pharmaceuticals 19 00130 g005
Pharmaceuticals 19 00130 g006
Figure 6. Interaction modes of (A) pictilisib (19) with PI3Kδ (PDB: 2WXP) and (B) quisinostat (20) with HDAC8 (PDB: 6HSK). Images generated using PyMOL (version 1.5.0.5) software.
Figure 6. Interaction modes of (A) pictilisib (19) with PI3Kδ (PDB: 2WXP) and (B) quisinostat (20) with HDAC8 (PDB: 6HSK). Images generated using PyMOL (version 1.5.0.5) software.
Pharmaceuticals 19 00130 g006
Pharmaceuticals 19 00130 g007
Figure 7. Rational design of ifupinostat (22).
Figure 7. Rational design of ifupinostat (22).
Pharmaceuticals 19 00130 g007
Pharmaceuticals 19 00130 g008
Figure 8. Enzymatic activities for HDAC and PI3K of fimepinostat (21) and compound 23 [55].
Figure 8. Enzymatic activities for HDAC and PI3K of fimepinostat (21) and compound 23 [55].
Pharmaceuticals 19 00130 g008
Pharmaceuticals 19 00130 g009
Figure 9. Identification of compound 25 [56].
Figure 9. Identification of compound 25 [56].
Pharmaceuticals 19 00130 g009
Pharmaceuticals 19 00130 g010
Figure 10. Design concept of compound 27 [57].
Figure 10. Design concept of compound 27 [57].
Pharmaceuticals 19 00130 g010
Pharmaceuticals 19 00130 g011
Figure 11. Molecular design of compound 28. * Selectivity index relative to other HDAC isoforms [58].
Figure 11. Molecular design of compound 28. * Selectivity index relative to other HDAC isoforms [58].
Pharmaceuticals 19 00130 g011
Pharmaceuticals 19 00130 g012
Figure 12. Molecular design, SAR and identification of compound 31 [59].
Figure 12. Molecular design, SAR and identification of compound 31 [59].
Pharmaceuticals 19 00130 g012
Pharmaceuticals 19 00130 g013
Figure 13. Concept design and identification of PI3K/HDAC multitarget inhibitor 35 [64].
Figure 13. Concept design and identification of PI3K/HDAC multitarget inhibitor 35 [64].
Pharmaceuticals 19 00130 g013
Pharmaceuticals 19 00130 g014
Figure 14. Molecular design of benzamide multitarget PI3K/HDAC inhibitors 37 and 38 [65].
Figure 14. Molecular design of benzamide multitarget PI3K/HDAC inhibitors 37 and 38 [65].
Pharmaceuticals 19 00130 g014
Table 1. Enzyme inhibition data for HDAC and PI3K for fimepinostat (21) and its prototypes 19 and 20 [46,47,48].
Table 1. Enzyme inhibition data for HDAC and PI3K for fimepinostat (21) and its prototypes 19 and 20 [46,47,48].
IC50 (nM)
HDACs
Compound1238457961011
Quisinostat (20)0.110.334.864.260.643.6911932.176.80.460.37
Fimepinostat (21)1.75.01.8191409674426554272.85.4
PI3Ks
Compoundαβδγ
Pictilisib (19)831455
Fimepinostat (21)195439311
Table 2. Active clinical trials with multitarget HDAC/PI3K inhibitors 21 and 22.
Table 2. Active clinical trials with multitarget HDAC/PI3K inhibitors 21 and 22.
InhibitorRealizadorIndicationPhaseNCT NumberStart Date
Fimepinostat (21)University of California, Los AngelesCushing diseaseIINCT0597175816 January 2025
University of California, San FranciscoDiffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, or Recurrent High-Grade Glioma INCT038934877 August 2019
Dana-Farber Cancer InstituteSolid Tumors, Brain Tumors or LynphomaINCT02909777October 2016
Ifupinostat (22)BeBetter Med Inc.DLBCL R/RIIINCT067922536 January 2025
BeBetter Med Inc.DLBCL R/RIINCT0607410715 June 2020
BeBetter Med Inc.DLBCL R/RINCT061643271 December 2023
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lima, A.D.S.; Lima, L.M. Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. Pharmaceuticals 2026, 19, 130. https://doi.org/10.3390/ph19010130

AMA Style

Lima ADS, Lima LM. Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. Pharmaceuticals. 2026; 19(1):130. https://doi.org/10.3390/ph19010130

Chicago/Turabian Style

Lima, Alef D. S., and Lídia M. Lima. 2026. "Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates" Pharmaceuticals 19, no. 1: 130. https://doi.org/10.3390/ph19010130

APA Style

Lima, A. D. S., & Lima, L. M. (2026). Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. Pharmaceuticals, 19(1), 130. https://doi.org/10.3390/ph19010130

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop